|
utilizing Christine UK's article on copper-binding I found info on uPA inhibitor
The company making the copper-binding compound has entered into an agreement with another company making the uPA inhibitor--so here is the news:
XOMA to Humanize Attenuon’s Novel Anti-Cancer Antibody
Applying Human EngineeringTM Technology to Advance Antibody Targeting
Urokinase Plasminogen Activator System
************************************************** *****************
Berkeley and San Diego, CA – October 3, 2006 -- XOMA Ltd. (Nasdaq: XOMA) and
Attenuon, LLC today announced an agreement for XOMA to utilize its Human
EngineeringTM (HETM) technology to humanize a monoclonal antibody targeting the
urokinase plasminogen activator (uPA) system for the treatment of cancer. The uPA
system plays a central role in multiple pathways and processes related to tumor growth,
metastasis, and angiogenesis (the growth of new blood vessels that feed tumors).
Attenuon will pay XOMA an up-front fee, development milestones, and royalties.
Attenuon will retain all development and commercialization rights to the antibody.
Additional financial terms were not disclosed.
|